XTL Biopharmaceuticals LTD: which funds bought and sold
Institutions that bought and sold XTL Biopharmaceuticals shares in Q2 2026, from the holdings they reported to the SEC on Form 13F for March 31, 2026 and June 30, 2026.
Between March 31, 2026 and June 30, 2026, 2 institutions that filed 13F reports for both quarters added to or opened positions in XTL Biopharmaceuticals, and 5 cut or closed them. Together they sold a net 65K shares, −89.6% on what they held at the start of the quarter. 1 opened a new position and 4 sold out entirely.
Bought, Q2 2026 2 institutions, 1 of them new holders Sold, Q2 2026 5 institutions, 4 of them sold out
Net change, all compared −65K shares (−89.6%)
Net change, active managers 0 shares (—), 0 bought, 0 sold
Buyers versus sellers
2 bought 5 sold
Active managers and hedge funds 0 bought · 0 sold · 0
Index fund managers 1 bought · 0 sold · +241
Other institutions 1 bought · 5 sold · −65K
Biggest buyers
| Institution | Change in shares | Shares June 30, 2026 | Value |
|---|---|---|---|
| Rhumbline Advisers Index funds | +241 +4.0% | 6,228 | $17,000 |
| UBS Group AG | +125 New position | 125 | $341 |
| Institution | Change in shares | Shares June 30, 2026 | Value |
|---|---|---|---|
| None of the active managers on our list. | |||
Biggest sellers
| Institution | Change in shares | Shares June 30, 2026 | Value |
|---|---|---|---|
| Noked Israel Ltd | −50K Sold out | 0 | — |
| Smartharvest Portfolios, LLC | −13K Sold out | 0 | — |
| Gamma Investing LLC | −2,175 −64.2% | 1,213 | $3,311 |
| Tower Research Capital LLC (TRC) | −244 Sold out | 0 | — |
| Morgan Stanley | −10 Sold out | 0 | — |
| Institution | Change in shares | Shares June 30, 2026 | Value |
|---|---|---|---|
| None of the active managers on our list. | |||
New positions
| Institution | Shares | Value June 30, 2026 |
|---|---|---|
| UBS Group AG | 125 | $341 |
Sold out
| Institution | Shares | Value March 31, 2026 |
|---|---|---|
| Noked Israel Ltd | 50K | $120,000 |
| Smartharvest Portfolios, LLC | 13K | $32,176 |
| Tower Research Capital LLC (TRC) | 244 | $588 |
| Morgan Stanley | 10 | $24 |
Who holds the shares
- Institutions reporting
- 3
- Ten largest holders
- 100.0% of 13F-reported shares
- Index fund managers
- 82.3% of 13F-reported shares
- Active managers and hedge funds
- 0.0% of 13F-reported shares
| Type | Bought | Sold | New | Sold out | Net change in shares | Net % |
|---|---|---|---|---|---|---|
| Active managers and hedge funds | 0 | 0 | 0 | 0 | 0 | — |
| Index fund managers | 1 | 0 | 0 | 0 | +241 | +4.0% |
| Other institutions | 1 | 5 | 1 | 4 | −65K | −98.0% |
← Back to XTL Biopharmaceuticals LTD · Insiders · Politicians